Bhanvi Satija

New Delhi

U.S. Health & Pharma Sector Specialist at Reuters

Covering U.S. Health and Pharma for Reuters. Views expressed are my own. RTs ≠ endorsements. Sporadic Twitter-er.

Featured in: Favicon

reuters.com (+1) Favicon

uol.com.br Favicon

msn.com

theguardian.com Favicon

terra.com.br Favicon

yahoo.com (+15) Favicon

aol.com

smh.com.au Favicon

thetimes.co.uk Favicon

usnews.com + 101 more

Articles

Hims to acquire UK-based startup Zava as it expands international presence

3 days ago | today.westlaw.com | Bhanvi Satija |Lincoln Feast |Sriparna Roy

NEW YORK (Reuters) -Telehealth platform Hims & Hers said on Tuesday it will acquire London-based startup Zava for an undisclosed amount, allowing it to launch its offerings in Germany, France and Ireland and reach more international patients.
米厚生省、薬価引き下げの具体目標を数週間内に業界へ通知

2 weeks ago | jp.reuters.com | Bhanvi Satija

トランプ米大統領が薬価の大幅引き下げを指示する大統領令に署名したことを受け、米厚生省は２０日、具体的な目標についてケネディ長官とメディケア・メディケイド・サービス・センター（ＣＭＳ）のオズ所長、製薬業界が数週間以内に共有することになると明らかにした。２０２４年６月撮影のイメージ写真（２０２５年ロイター/Dado Ruvic/Illustration）［２０日ロイター］ - トランプ米大統領が薬価の大幅引き下げを指示する大統領令に署名したことを受け、米厚生省は２０日、具体的な目標についてケネディ長官とメディケア・メディケイド・サービス・センター（ＣＭＳ）のオズ所長、製薬業界が数週間以内に共有することになると明らかにした。ケネディ氏は「製薬業界が米国の患者向けの薬価引き下げに全力を注ぐことを期待している。さもなければ彼らが確実にそうするようわれわれが手を打つだろう」と強調した。トランプ氏は処方薬の価格を５９─９０％引き下げたい意向。大統領令では、薬価に「最恵国待遇（ＭＦＮ）」の仕組みを導入し、他の先進国の最も低い価格に連動させることを狙っている。...
US health authorities to set targets for lowering drug prices

2 weeks ago | marketscreener.com | Bhanvi Satija

Published on 05/20/2025 at 09:55, updated on 05/20/2025 at 12:20 (Reuters) -The U.S. Department of Health and Human Services said on Tuesday it was setting most-favored-nation prescription drug pricing targets following an executive order from President Donald Trump last week aimed at lowering the prices of branded medicines for U.S. consumers.
US health authorities to set targets for lowering drug prices

2 weeks ago | uk.marketscreener.com | Bhanvi Satija

Published on 20/05/2025 at 14:55, updated on 20/05/2025 at 17:20 (Reuters) -The U.S. Department of Health and Human Services said on Tuesday it was setting most-favored-nation prescription drug pricing targets following an executive order from President Donald Trump last week aimed at lowering the prices of branded medicines for U.S. consumers.
US health authorities to set targets for lowering drug prices

2 weeks ago | yahoo.com | Bhanvi Satija

By Bhanvi Satija(Reuters) - The U.S. Department of Health and Human Services said on Tuesday it would set drug prices pegged to the lowest level paid by other high-income countries following an executive order from President Donald Trump last week aimed at lowering the prices of branded medicines for U.S. consumers.
US health authorities to set targets for lowering drug prices

2 weeks ago | today.westlaw.com | Ahmed Aboulenein |Bhanvi Satija |Katharine Jackson |Rami Ayyub

(Reuters) - The U.S. Department of Health and Human Services said on Tuesday it would set drug prices pegged to the lowest level paid by other high-income countries following an executive order from President Donald Trump last week aimed at lowering...
Bayer US head says FDA chief reassured pharma executives of timely reviews

2 weeks ago | pharma.economictimes.indiatimes.com | Bhanvi Satija |Michael Erman

New York: Bayer Pharmaceuticals' chief operating officer said the head of the top U.S. drug regulator recently reassured industry executives that the Food and Drug Administration would meet its targets for reviews despite recent job cuts and a restructuring. "We're looking at an FDA and scientific review staff that is stable, engaged and meeting its deadlines," Sebastian Guth, who oversees Bayer's U.S. operations, said in an interview.
Bayer US head says FDA chief reassured pharma executives of timely reviews

3 weeks ago | whbl.com | Bhanvi Satija |Michael Erman

By Bhanvi Satija and Michael ErmanNEW YORK (Reuters) -Bayer Pharmaceuticals’ chief operating officer said the head of the top U.S. drug regulator recently reassured industry executives that the Food and Drug Administration would meet its targets for reviews despite recent job cuts and a restructuring. “We’re looking at an FDA and scientific review staff that is stable, engaged and meeting its deadlines,” Sebastian Guth, who oversees Bayer’s U.S. operations, said in an interview.
Bayer US head says FDA chief reassured pharma executives of timely reviews

3 weeks ago | kfgo.com | Bhanvi Satija |Michael Erman

By Bhanvi Satija and Michael ErmanNEW YORK (Reuters) -Bayer Pharmaceuticals’ chief operating officer said the head of the top U.S. drug regulator recently reassured industry executives that the Food and Drug Administration would meet its targets for reviews despite recent job cuts and a restructuring. “We’re looking at an FDA and scientific review staff that is stable, engaged and meeting its deadlines,” Sebastian Guth, who oversees Bayer’s U.S. operations, said in an interview.
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge

1 month ago | today.westlaw.com | Bhanvi Satija |Anil D'Silva |Bill Berkrot |Patrick Wingrove

(Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell roughly 10% on investor worries that the...